The global biopharmaceutical CMO and CRO market size is expected to reach US$ 59.4 billion by 2030 from US$ 29.1 billion in 2020 and is expected to grow at an impressive double-digit rate of 7.4% from 2021 to 2030.
The study includes drivers and restraints of this market. The study provides an analysis of the global biopharmaceutical CMO and CRO Market for the period 2017-2030, wherein 2021 to 2030 is the forecast period and 2020 is considered as the base year.
We customize your report according to your research need. REQUEST CUSTOMIZED COPY OF REPORT (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/customization/1289
Crucial factors accountable for market growth are:
- Rapidly growing biopharmaceutical industry
- Rising demand for the biopharmaceutical products
- Increased participation of medium and small-sized enterprises in biologics
- Growing government expenditure on building sophisticated healthcare infrastructure
- Increasing adoption of biopharma drugs and therapeutics
- Rising burden of diseases amongst the population
- Presence of numerous CMOs and CROs in the market
Scope of the Biopharmaceutical CMO and CRO Market Report
Report Coverage | Details |
Market Size in 2030 | USD 59.4 Billion |
Growth Rate from 2021 to 2030 | CAGR of 7.4% |
Base Year | 2021 |
Forecast Period | 2021 to 2030 |
Segments Covered | Product Type, Source Type, Service Type |
Regional Scope | North America, APAC, Europe, Latin America, MEAN, Rest of the World |
Companies Mentioned | TOYOBO Co. Ltd., Samsung Biologics, LabCorp, Lonza, BoehringerIngelheim, Patheon, CMC Biologics, JRS Pharma, PRA Health Sciences, RentschlerBiotechnologie, FUJIFILM Diosynth Biotechnologies, WuXi Biologics |
Regional Snapshots
North America is the leading biopharmaceutical CMO and CRO market. The US accounts for around 33.33% of the global biopharmaceutical CMO market and is also the leader in biopharmaceutical CRO market. As per the Pharmaceutical Research and Manufacturers Association, US has the property rights on majority of the new medicines. North America is characterized by supportive setting for the commercialization and development of medicines, rewards to the developers in the form of intellectual property rights, and supportive regulatory framework for the biopharmaceuticals. This helps in attracting capital investments in North America region for the development of biopharmaceutical companies. This is a significant growth factor that boosts the growth and development of the biopharmaceutical CMO and CRO market in the region.
Asia Pacific is estimated to be the fastest-growing region, owing to enhanced regulatory framework regarding the biopharmaceuticals, greater supply of capital, and support from the government. In South Korea, the Samsung Biologics witnessed a spike in its sales by 56% in 2017. Further, the Celltrion Group of South Korea acquired European Medicines Agency approval for it biosimilar product called Herzuma, in 2018. Further, in India, Biocon received FDA approval for its biosimilar product called Ogivri in 2017. China, the second largest market for the biopharmaceuticals is attracting FDIs for setting up manufacturing units that exponentially propels the biopharmaceutical CMO and CRO market growth in Asia Pacific region.
Why should you invest in this report?
If you are aiming to enter the global biopharmaceutical CMO and CRO market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for biopharmaceutical CMO and CRO are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Report Highlights
- By service, the contract manufacturing segment led the global biopharmaceutical CMO and CRO market with remarkable revenue share in 2020. This is attributed to the growing participation of the small and medium conventional pharmaceutical developers in the biopharmaceutical industry owing to its market attractiveness.
- By source, the mammalian segment led the global biopharmaceutical CMO and CRO market with remarkable revenue share in 2020. This is attributed to the growing importance of biotherapies namely, monoclonal antibodies, vaccines, and blood factors are developed using mammalian cell culture. Moreover, the antibody products are the dominant commercial products that foster the segment growth.
- By product type, the biologics segment led the global biopharmaceutical CMO and CRO market with remarkable revenue share in 2020. Biologics gained traction when it opened up the opportunities for the treatment of cancer. Moreover, higher approval rate of biologic medicines is fostering its adoption at a rapid pace among the consumers.
Market Dynamics:
Drivers
The global biopharmaceutical CMO and CRO market is primarily driven by the increasing popularity and increasing investments by the key players in the biopharmaceutical industry for the development of cost-effective and innovative drugs.
Restraints
The lack of proper healthcare infrastructure in the underdeveloped economies, lack of awareness regarding technologically advance biopharma products, and high costs involved are the major factors that may hamper the market growth.
Opportunities
The growing research and development activities carried on by the key market players to develop effective drugs and medicines for various serious illnesses and disease like cancer may open up new opportunities in the upcoming future.
Challenges
Lack of adequate capital in the hands of the small pharmaceutical developers who have interests in shifting towards the biopharmaceuticals is a major challenge that may slow down the growth of the global biopharmaceutical CMO and CRO market.
Recent Developments
- In May 2019, Samsung Biologics entered into a contract with GI Innovation for development of Immunochemotherapy. Under this contract, Samsung Biologics will develop a new drug through a combination of protein drugs and human micro-organisms.
The key players operating in the biopharmaceutical CMO and CRO market are Lonza, Samsung Biologics, Patheon, CMC Biologics, TOYOBO Co. Ltd., JRS Pharma, RentschlerBiotechnologie, FUJIFILM Diosynth Biotechnologies, WuXi Biologics, BoehringerIngelheim, PRA Health Sciences, LabCorp.
Market Segmentation:
By Service
- Contract Manufacturing
- Process Development
- Upstream
- Downstream
- Fill & Finish Operations
- Packaging
- Analytical & QC studies
- Process Development
- Contract Research
- Inflammation & Immunology
- Oncology
- Neuroscience
- Cardiology
- Others
By Source
- Mammalian
- Non-Mammalian
By Product
- Biosimilars
- Biologics
- Vaccines
- Monoclonal antibodies (MABs)
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others
Regional Analysis:
The geographical analysis of the global biopharmaceutical CMO and CRO market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American market is again segmented into the US, Canada, and Mexico. Coming to the European market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global biopharmaceutical CMO and CRO Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global biopharmaceutical CMO and CRO market in 2030?
- What is the expected CAGR for the biopharmaceutical CMO and CRO market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global biopharmaceutical CMO and CRO market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Source Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Biopharmaceutical CMO and CRO Market, By Product
7.1. Biopharmaceutical CMO and CRO Market, by Product Type, 2021-2030
7.1.1. Biologics (Vaccines, Monoclonal antibodies (MABs), Recombinant Proteins, Others)
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Biosimilars
7.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Biopharmaceutical CMO and CRO Market, By Service
8.1. Biopharmaceutical CMO and CRO Market, by Service, 2021-2030
8.1.1. Contract Manufacturing (Process Development, Fill & Finish Operations, Analytical & QC studies, Packaging)
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Contract Research (Inflammation & Immunology, Cardiology, Oncology, Neuroscience, Others)
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Biopharmaceutical CMO and CRO Market, By Source
9.1. Biopharmaceutical CMO and CRO Market, by Source, 2021-2030
9.1.1. Mammalian
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Non-Mammalian
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Biopharmaceutical CMO and CRO Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.2. Market Revenue and Forecast, by Service (2017-2030)
10.1.3. Market Revenue and Forecast, by Source (2017-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.1.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.1.5.3. Market Revenue and Forecast, by Source (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.2. Market Revenue and Forecast, by Service (2017-2030)
10.2.3. Market Revenue and Forecast, by Source (2017-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.2.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.2.5.3. Market Revenue and Forecast, by Source (2017-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Service (2017-2030)
10.2.6.3. Market Revenue and Forecast, by Source (2017-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.7.2. Market Revenue and Forecast, by Service (2017-2030)
10.2.7.3. Market Revenue and Forecast, by Source (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.2. Market Revenue and Forecast, by Service (2017-2030)
10.3.3. Market Revenue and Forecast, by Source (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.3.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.3.5.3. Market Revenue and Forecast, by Source (2017-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Service (2017-2030)
10.3.6.3. Market Revenue and Forecast, by Source (2017-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.7.2. Market Revenue and Forecast, by Service (2017-2030)
10.3.7.3. Market Revenue and Forecast, by Source (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.4.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.4.5.3. Market Revenue and Forecast, by Source (2017-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Service (2017-2030)
10.4.6.3. Market Revenue and Forecast, by Source (2017-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.7.2. Market Revenue and Forecast, by Service (2017-2030)
10.4.7.3. Market Revenue and Forecast, by Source (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.5.3. Market Revenue and Forecast, by Source (2017-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.5.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.5.5.3. Market Revenue and Forecast, by Source (2017-2030)
Chapter 11. Company Profiles
11.1. Lonza
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. JRS Pharma
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Samsung Biologics
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. CMC Biologics
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. TOYOBO Co. Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. RentschlerBiotechnologie
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. FUJIFILM Diosynth Biotechnologies
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. WuXi Biologics
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Patheon
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. BoehringerIngelheim
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. PRA Health Sciences
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. LabCorp
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1289
About Us:
Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and among different ventures present globally.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
0 Comments